Protective Effect of Garcinia Kola (Kolaviron) Extract on Predisposition of Rats to Cardiovascular Diseases Following Separate Administration of Amodiaquine and Artesunate

This study was carried out to investigate the cardiovascular effect of administration of antimalarial drugs amodiaquine and artesunate and the efficacy of Garcinia kola extract (kolaviron) in protecting against such possible effect. Thirty (30) adult male albino rats divided into six (6) groups were used in this study. Groups D, E and F were treated with 100 mg/Kg b. w of the extract twice daily for the first one week and 200 mg/Kg b. w. /day for the subsequent three (3) weeks. Amodiaquine (10mg/Kg. b. w. /day) was administered orally for four (4) days into rats in groups A and E while rats in groups B and F were treated with artesunate (5mg/Kg b. w. /day) for four (4) days. Group C rats (normal control) were treated with normal saline. All the rats were sacrificed after four (4) weeks treatment period. Blood was withdrawn by cardiac puncture while the liver, kidney, stomach and heart were removed, cleansed and weigh. Total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides were measured in the serum, while total fibrinogen, platelet count, red blood cell and white blood cell count were measured in the whole blood. The artherogenic and coronary risk index were also determined. Results indicate that both amodiaquine and artesunate predispose to cardiovascular disease, however the effect was more pronounced with artesunate than amodiaquine. The result also suggests that both drugs could increase the risk of coronary and artherogenic diseases and that Garcinia kola do not prevent the cardiotoxicity and coronary risk effect.     

全复配食用菌提取物对C26荷瘤小鼠的抑瘤作用和免疫功能影响

背景与目的:食用真菌在医疗保健领域的研究展现出强大的应用潜力.该课题探讨全复配食用菌提取物的抗肿瘤作用及对荷瘤小鼠免疫功能的影响.方法:小鼠随机编号分组,其中预防组预先给予全复配食用菌提取物灌胃2周,每天1次,之后各组均接种C26细胞建立荷瘤小鼠模型,接种后第2天给小鼠予以不同制剂灌胃(空白组灌0.9%氯化钠溶液,治疗组、预防阻灌复配食用菌提取物,CTX阳性组腹腔注射CTX)每天1次,观察记录小鼠一般状态,2周后处死小鼠无菌取脾脏、取瘤称重.MTT法检测小鼠脾淋巴细胞转化功能,乳酸脱氢酶(LDH)法检测NK细胞杀伤活性.结果:复配食用菌提取物预防组对小鼠C26肿瘤有30.4%的抑制率;小鼠脾淋巴细胞在ConA刺激下的增殖能力和NK细胞杀伤功能均显著高于空白组.结论:复配食用菌提取物预防性摄入对再接种C26小鼠有抑瘤和免疫增强作用.     

生物标志物与非小细胞肺癌治疗结局相关

血管内皮生长因子（VEGF）和可溶性VEGF受体2（sVEGFR-2）由VEGF通路抑制因子所调控,化疗、VEGFR抑制剂或两者联合治疗是否可引起细胞因子和血管生成因子（CAFs）的改变,而这些改变是否又能预示临床获益？     

Feeding strategies for premature infants: randomized trial of gastrointestinal priming and tube-feeding method

BACKGROUND: Data on enteral feeding management of premature infants are limited and often not the subject of randomized clinical trials. Several small studies suggest benefits from the early initiation of feeding, but do not assess the combined effects of time of initiation of feeding, tube-feeding method, and type of milk used. Either singly or in combination, these treatments may affect growth, bone mineralization, biochemical measures of nutritional status, and feeding tolerance, and, ultimately, the duration of hospitalization. METHODS: A total of 171 premature infants, stratified by gestational age (26 to 30 weeks) and diet (human milk or preterm formula) were assigned randomly among four treatment combinations in a balanced two-way design comparing the presence or absence of gastrointestinal (GI) priming for 10 days and continuous infusion versus intermittent bolus tube-feeding. RESULTS: The major outcome, time required for infants to attain full oral feeding, was similar among treatments. GI priming was not associated with any measured adverse effect and was associated with better calcium and phosphorus retention, higher serum calcium and alkaline phosphatase activity, and shorter intestinal transit times. The bolus tube-feeding method was associated with significantly less feeding intolerance and greater rate of weight gain than the continuous method. In addition, the greater the quantity of human milk fed, the lower the morbidity. CONCLUSIONS: Early GI priming with human milk, using the bolus tube-feeding method, may provide the best advantage for the premature infant.     

Dermoscopy is a suitable method for the observation of the pregnancy-related changes in melanocytic nevi

BACKGROUND: It is a common opinion that expansion and darkening in melanocytic nevi may occur during pregnancy. The main problem is that whether it is a usual finding, or it is a condition that requires suspicion about melanoma. OBJECTIVES: It was aimed to find the changes that might occur in the sizes and structures of melanocytic nevi during pregnancy. METHODS: Ninety-seven nevi of the 56 pregnant women in the first trimester were evaluated in the study. The localization and size of the nevi were recorded on a standard body diagram. After clinical examination, dermoscopic analyses were applied. Pattern analyses were done, and total dermoscopy scores (TDS) were calculated by applying ABCD scoring system. All subjects were seen again during the third trimester. RESULTS: There was a statistically significant difference between the mean diameters of nevi in the first and third trimester (P = 0.001). Of nevi whose diameters increased, 10 (50.00%) were localized on the front of body, 6 (30.00%) on the face and neck, 3 (15.00%) on the legs, and 1 (5.00%) on the back. The enlargement in diameters was more significant on the front of the body, but there was no statistically significant difference. Compared according to the pattern analysis, new dot formation was observed only on the structure of six nevi during the last trimester. Four of them were localized on the front of the body. There was statistically significant increase in mean TDS in comparison between the first and third trimesters (P = 0008). CONCLUSIONS: During the pregnancy, widening in diameters and structure changes of nevi may be seen especially on the front of the body. We also think that these findings might be connected with expansion of the skin during pregnancy. Dermoscopic controls are the first choice of method to analyse the nevi since the patient may not recognize these changes.     

Expression of mutated glucocerebrosidase alleles in human cells

Gaucher disease is a heterogeneous disease characterized by impaired activity of the lysosomal enzyme glucocerebrosidase. This heterogeneity is attributed to a large number of mutations in the corresponding gene. In order to test the biochemical properties of some mutations prevalent among Israeli populations, the normal human glucocerebrosidase cDNA and cDNAs carrying mutations N370S, L444P, D409H, recTL, recNcil, P415R and 84GG were coupled to the T7 RNA polymerase promoter in a vaccinia virus- derived expression vector (pTM-1). Recombinant viruses were produced and used to infect human tissue culture cells. RNA and protein stability, recognition by anti-glucocerebrosidase monoclonal antibodies and intracellular enzymatic activity were measured. The results demonstrated that the D409H allele directed synthesis of cytoplasmic RNA with decreased stability compared with its normal counterpart or other mutated forms. The D409H and L444P mutated proteins had lower stability than that of their normal counterpart, while the recNcil- mutated protein was more stable. Only glucocerebrosidase forms harboring leucine at position 444 were recognized by the anti- glucocerebrosidase monoclonal antibodies used (8E4 and 2C7). Measurements of enzymatic activity of the recombinant proteins in cells loaded with a fluorescent glucosylceramide demonstrated that the N370S mutated enzyme had activity similar to that of the normal enzyme. The other mutated enzymes exhibited varying degrees of activities, generally corresponding to the phenotypes with which they are associated. The results presented demonstrate the use of the vaccinia virus-derived expression system and of loading living cells with fluorescent substrate as efficient tools for studying mutants in Gaucher disease and in other lysosomal diseases.